Needham analyst David Saxon has maintained their neutral stance on BLCO stock, giving a Hold rating on October 27.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Saxon has given his Hold rating due to a combination of factors including Bausch + Lomb Corporation’s solid performance in the third quarter of 2025. The company’s revenue met expectations, and earnings surpassed them, indicating a stable growth in Vision Care and Surgical segments, along with an improvement in Ophthalmic Pharmaceuticals. However, despite these positive results, Saxon remains cautious due to uncertainties surrounding the company’s separation from its parent, Bausch Health Companies.
Additionally, the introduction of a ‘Financial Excellence’ pillar in BLCO’s strategic roadmap suggests a shift towards a focus on profitable growth. The upcoming Investor Day is expected to provide further insights into the company’s pipeline and profitability potential. Until more clarity is obtained on these fronts, Saxon maintains a Hold rating, reflecting a balanced view of the company’s current performance and future uncertainties.
In another report released on October 27, Barclays also maintained a Hold rating on the stock with a $16.00 price target.